These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 17264511)

  • 1. Combination antiplatelet therapy with aspirin and clopidogrel: the role of antecedent and concomitant doses of aspirin. An analysis of 711 patients.
    Serebruany VL; Malinin AI; Atar D
    Cardiology; 2007; 107(4):307-12. PubMed ID: 17264511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
    Serebruany VL; Malinin AI; Pokov AN; Hanley DF
    Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial.
    Serebruany VL; Malinin AI; Jerome SD; Lowry DR; Morgan AW; Sane DC; Tanguay JF; Steinhubl SR; O'connor CM
    Am Heart J; 2003 Oct; 146(4):713-20. PubMed ID: 14564328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy.
    Kastrati A; von Beckerath N; Joost A; Pogatsa-Murray G; Gorchakova O; Schömig A
    Circulation; 2004 Oct; 110(14):1916-9. PubMed ID: 15262828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consistent platelet inhibition during long-term maintenance-dose clopidogrel therapy among 359 compliant outpatients with documented vascular disease.
    Serebruany VL; Malinin AI; Atar D; Hanley DF
    Am Heart J; 2007 Mar; 153(3):371-7. PubMed ID: 17307414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rebound platelet activation after termination of prasugrel and aspirin therapy due to confirmed non-compliance in patient enrolled in the JUMBO Trial.
    Serebruany VL; Midei MG; Meilman H; Malinin AI; Lowry DR
    Int J Clin Pract; 2006 Jul; 60(7):863-6. PubMed ID: 16846403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease.
    Klinkhardt U; Bauersachs R; Adams J; Graff J; Lindhoff-Last E; Harder S
    Clin Pharmacol Ther; 2003 Mar; 73(3):232-41. PubMed ID: 12621388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease.
    Serebruany V; Pokov I; Kuliczkowski W; Chesebro J; Badimon J
    Thromb Haemost; 2008 Jul; 100(1):76-82. PubMed ID: 18612541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.
    Reaume KT; Regal RE; Dorsch MP
    Ann Pharmacother; 2008 Apr; 42(4):550-7. PubMed ID: 18319394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
    Motovska Z; Kala P
    Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance.
    Lev EI; Patel RT; Maresh KJ; Guthikonda S; Granada J; DeLao T; Bray PF; Kleiman NS
    J Am Coll Cardiol; 2006 Jan; 47(1):27-33. PubMed ID: 16386660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of increased aspirin dose versus combined aspirin plus clopidogrel therapy in patients with diabetes mellitus and coronary heart disease and impaired antiplatelet response to low-dose aspirin.
    Duzenli MA; Ozdemir K; Aygul N; Soylu A; Tokac M
    Am J Cardiol; 2008 Aug; 102(4):396-400. PubMed ID: 18678294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in diabetic patients: the PLavix Use for Treatment Of Diabetes (PLUTO-Diabetes) trial.
    Serebruany VL; Malinin AI; Pokov A; Barsness G; Hanley DF
    Am Heart J; 2008 Jan; 155(1):93.e1-7. PubMed ID: 18082496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?
    Bliden KP; DiChiara J; Tantry US; Bassi AK; Chaganti SK; Gurbel PA
    J Am Coll Cardiol; 2007 Feb; 49(6):657-66. PubMed ID: 17291930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The additive antiplatelet action of clopidogrel in patients with coronary artery disease treated with aspirin.
    Dropinski J; Jakiela B; Sanak M; Wegrzyn W; Biernat M; Dziedzina S; Plutecka H; Szczeklik A
    Thromb Haemost; 2007 Jul; 98(1):201-9. PubMed ID: 17598014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiplatelet effects of angiotensin-converting enzyme inhibitors compared with aspirin and clopidogrel: a pilot study with whole-blood aggregometry.
    Bauriedel G; Skowasch D; Schneider M; Andrié R; Jabs A; Lüderitz B
    Am Heart J; 2003 Feb; 145(2):343-8. PubMed ID: 12595854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of uniform platelet activation in patients after ischemic stroke and choice of antiplatelet therapy.
    Serebruany VL; Malinin AI; Oshrine BR; Sane DC; Takserman A; Atar D; Hennekens CH
    Thromb Res; 2004; 113(3-4):197-204. PubMed ID: 15140583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy.
    Angiolillo DJ; Bernardo E; Capodanno D; Vivas D; Sabaté M; Ferreiro JL; Ueno M; Jimenez-Quevedo P; Alfonso F; Bass TA; Macaya C; Fernandez-Ortiz A
    J Am Coll Cardiol; 2010 Mar; 55(11):1139-46. PubMed ID: 20223369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiplatelet effect of clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions--limited inhibition of the P2Y12 receptor.
    Lepäntalo A; Virtanen KS; Reséndiz JC; Mikkelsson J; Viiri LE; Karhunen PJ; Lassila R
    Thromb Res; 2009 Jun; 124(2):193-8. PubMed ID: 19232433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized comparison of the effects of ASA plus clopidogrel versus ASA alone on early platelet activation in acute coronary syndromes with elevated high-sensitivity C-reactive protein and soluble CD40 ligand levels.
    Vavuranakis M; Latsios G; Aggelis D; Bosinakou I; Karambelas I; Tousoulis D; Toutouzas K; Stefanadis C
    Clin Ther; 2006 Jun; 28(6):860-71. PubMed ID: 16860169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.